Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).
Masaya KoshizakaKo IshikawaRyoichi IshibashiYoshiro MaezawaKenichi SakamotoDaigaku UchidaSusumu NakamuraMasaya YamagaHidetaka YokohAkina KobayashiShunichiro OnishiKazuki KobayashiJun OginoNaotake HashimotoHirotake TokuyamaFumio ShimadaEmi OharaTakahiro IshikawaMayumi ShojiShintaro IdeKana IdeYusuke BabaAkiko HattoriTakumi KitamotoTakuro HorikoshiRyouta ShimofusaSho TakahashiKengo NagashimaYasunori SatoMinoru TakemotoL Kristin NewbyKoutaro Yokotenull nullPublished in: Journal of diabetes investigation (2020)
There were no adverse effects on bone or muscle when sitagliptin was used in combination with either ipragliflozin or metformin. However, ipragliflozin combination increased the levels of TRACP-5b. A long-term study is required to further understand the effects of this TRACP-5b increase caused by ipragliflozin.